Skin indications innovative drug research and development company Troy has recruited a "big general".
On the first day of January 2022, Jiaxing Tecolo Biotechnology Co., Ltd. (hereinafter referred to as "Tecolo") announced the appointment of Ms. Lu Jiandong as the Company's Chief Financial Officer.
Ms. Lui previously served as an Executive Director and CFO of The NASDAQ-listed Ruisi Education Group, and earlier served as a Managing Director of the well-known J.P. Morgan Investment Bank, a Chief Operating Officer (COO) of J.P. Morgan China Securities Joint Venture, and a Managing Director and Head of China at J.P. Morgan Asset Management. Ms. Lui has extensive experience in capital markets and corporate operation management. After taking up her new role, Ms. Lui will assist the founder Dr. Wang Zengquan to bring the company into a new stage of development and make full preparations for the company's listing.
In the eyes of market participants, the establishment of the CFO position is an inevitable product of the development of the corporate governance structure to a new stage, and the appointment of the CFO means that Turkoro will enter a new period of development.
According to public information, Turkoro is a small molecule drug research and development innovation enterprise focusing on the research and development of new drugs for skin diseases. The company is committed to becoming the world's leading dermatology new drug research and development platform, developing and listing First-in-Class or the best-in-class global new drugs for major skin-related diseases, providing patients around the world with more efficient, safer and lower cost new drug products based on new mechanisms.
New aid complements a key part of corporate governance
Corporate financing, financial management and corporate governance are the core of enterprise operation and management, and the CFO directly bound to corporate financing and financial management is an indispensable core figure for the development of enterprise scale and standardized development.
Ms. Lu Jiandong, who was appointed as CFO by Tekoro, has 12 years of investment banking experience, 2 years of private equity financing experience, and 5 years of corporate operation management experience, and is familiar with capital markets, corporate finance, strategic mergers and acquisitions, financial management, investor relations, human resource management, corporate governance, internal control and compliance. Ms. Lu will take full responsibility for this aspect after becoming the new CFO of Tecorro.
Ms. Lu Jiandong, who recently joined Tekoro, said: "Tekoro is one of the most innovative and energetic professional companies in the field of skin diseases, and I am very happy to be a member of this start-up company, and I hope that in the future development of the company, together with the company's colleagues, we will do our best to strive to make Tekoro company the ultimate in internationalization, commercialization and management modernization."
Commenting on the addition of Lu Jiandong, Dr. Wang Zengquan, General Manager of Turkoro, said: "We are very pleased and honored to have Ms. Lu Jiandong join Tokoro and serve as the company's Chief Financial Officer (CFO). Ms. Lui has an excellent educational background and rich working experience and experience in finance, business and operations management. After several years of early research and development in the field of new drug research and development of skin diseases, the drug pipeline layout of several major skin diseases has begun to take shape, and in the next two years, multiple drug pipelines will enter the clinical research stage, and the company will enter a period of rapid development. The rapid development of the company has higher requirements for the company in terms of management, operation and standardization. The addition of Jiandong can undoubtedly make up for the needs of the company's development in this regard, which is a 'homeopathy' and a major event in the development of the company. I believe that Jiandong and our colleagues will work together, and we will seize the good opportunity of China's biomedical development, with the support of the government and fund companies, and we will jointly build Tekro into a world-class new drug research and development company for skin diseases that is localized in China."
Enter a new stage of development
At the same time as the appointment of CFO, Tekro's office in Shanghai was also moved into a new location at 60 Naxian Road, Pudong New Area, Shanghai. Initiatives such as the expansion of the management team and the upgrading of the office environment mark the entry of Tekoro into a new stage of development.
New location for Tekuro's Shanghai office
As an innovative company focusing on the development of new drugs for dermatological diseases, Tekoro has built a first-of-its-kind or best-in-class drug candidate pipeline for androgenic alopecia and autoimmune and inflammatory skin diseases.
In the field of hair loss, TDM-105795, the first clinical drug of Tecorro, has been shown in the preclinical animal efficacy data that the drug has the advantages of rapid efficacy and fewer side effects compared with existing drugs in the treatment of seborrheic alopecia (also known as androgenic alopecia). At present, the product has been carried out in the United States for clinical research in patients with hair loss, and the Phase I SAD trial (Phase I SAD trial) has been successfully concluded, and it is about to enter the Phase I MAD trial. The Hair Regeneration Program is expected to enter the U.S. Clinical Phase II Trial in the second half of 2022.
In terms of inflammatory skin diseases, the company focuses on the selection of highly differentiated and innovative Jak small molecule inhibitor drugs for different skin disease types to promote research and development, and now has a strong intellectual property foundation, and multiple series of compounds are simultaneously promoted in the development of eczema, psoriasis and lupus erythematosus and other diseases.
Among them, the preliminary efficacy results of the eczema project showed that the drug candidate had obvious advantages in efficacy, the efficacy was stronger than that of the PDE4 inhibitors that had been listed, and it had the same efficacy compared with glucodermic hormone drugs without adverse side effects of hormones on the skin. The eczema program is expected to file for Clinical Phase I in the second quarter of 2022. The company's new drug candidates for psoriasis and lupus erythematosus will also gradually enter the clinical trial declaration stage.
Three months ago, Turcorro also announced the appointment of Arthur P. Bertolino, MD, as the company's Chief Medical Officer. At the same time, Professor Xiang Leihong, a dermatologist at Fudan University School of Medicine, Dr. John Mao, a senior drug research and development expert in the San Francisco Bay Area, Professor Gary J. Fisher, a biologist at the University of Michigan, and Dr. Arthur P. Bertolino, were hired as members of the company's scientific advisory board.
The relevant appointments also provide a strong guarantee for all aspects of the company from pre-research and development to late clinical practice, which will help the company to lay out the pre-drug research pipeline and accelerate the subsequent multiple clinical pipeline projects into clinical research, ensuring the efficiency and quality of clinical research and development of innovative drugs. According to another introduction, at present, Tecorro still holds dozens of patents at home and abroad, which also lays a solid foundation for the company to develop innovative drugs with global intellectual property protection and international leadership.